TScan Therapeutics Inc
tscan.comWhat Do They Do?
Develops engineered T-cell therapies for patients with blood cancers and solid tumors, and identifies potential treatment targets for autoimmune disorders.
10-K for FY2025, filed Mar 4, 2026We are a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered…View ↗
We are further expanding our hematologic (heme) malignancies program with the addition of TCRs targeting other HLA types. TSC-102-A01 and…View ↗
We are also developing multiple TCR-T therapy product candidates for the treatment of solid tumors. One of the challenges of treating solid…View ↗
While primarily focused on oncology, we believe our target discovery platform is well suited to identify targets that cause T cell-driven…View ↗
How Do They Make Money?
Revenue has come from partner research and licensing: Amgen paid an upfront amount for Crohn’s disease target discovery, with potential milestone payments tied to development and sales and royalties if products are sold. TScan has not earned revenue from therapy sales.
10-K for FY2025, filed Mar 4, 2026To date, our revenue has primarily been derived from our collaboration and licensing agreements, which have been in the scope of ASC 606…View ↗
On May 8, 2023, the Company entered into a Collaboration Agreement with Amgen Inc. (the Amgen Agreement) to identify antigens recognized by…View ↗
The collaboration included an upfront fee of $30.0 million. We have identified performance obligations for research and development…View ↗
Opportunistically pursue strategic partnerships and collaborations to maximize the full potential of our platform. Our platform represents…View ↗
$10.3M
-
10-K for FY2025, filed Mar 4, 2026
$10.3M ↗
Who Are Their Customers?
Amgen collaborated with TScan on Crohn’s disease target discovery and held global rights to develop and commercialize resulting products; it later gave notice to terminate the agreement.
10-K for FY2025, filed Mar 4, 2026 8-K, filed Aug 18, 2026
Do Revenues Turn Into Profits?
No. It lost $129.8M in FY2025.
10-K for FY2025, filed Mar 4, 2026
−$135.8MView ↗
10-K for FY2025, filed Mar 4, 2026
−$129.8MView ↗
10-K for FY2025, filed Mar 4, 2026
−$139.7MView ↗
How Are They Changing?
-
Sep 2, 2026
Pauses TSC-101 Phase 3 enrollment and reprioritizes its pipeline
TScan paused enrollment in ALLOHA-2, plans an approximately 75% workforce reduction, and received a Nasdaq minimum-bid-price deficiency notice.
Sources
8-K, filed Sep 2, 2026
On September 2, 2026, TScan Therapeutics, Inc. (the “Company”) initiated a prioritization strategy by which the Company will prioritize the…View ↗
-
Aug 18, 2026
Amgen gives notice to end Crohn’s disease research collaboration
Termination is scheduled for November 10, 2026; TScan says it does not expect future milestone or royalty payments, subject to exceptions.
Sources
8-K, filed Aug 18, 2026
On August 12, 2026, TScan Therapeutics, Inc. (the “Company”) received notice from Amgen Inc. (“Amgen”) of its election to terminate, in its…View ↗
Flat. Revenue was $10.3M in FY2025, about the same as the $10.1M of FY2021.
In vivo solid-tumor engineering
The solid-tumor program adds an in vivo engineering approach intended to deliver off-the-shelf multiplex therapies, alongside customized TCR-T treatments.
10-K for FY2022, filed Mar 8, 2023 10-K for FY2025, filed Mar 4, 2026
Who Do They Compete With?
Competes with Immatics, Adaptimmune Therapeutics, Affini-T Therapeutics, Medigene, T-Knife, Immunocore Holdings, 3T Biosciences, Iovance Biotherapeutics, Instil Bio, Kite Pharma, Juno Therapeutics, Regeneron Pharmaceuticals, AstraZeneca, Legend Biotech, Autolus Therapeutics, Sana Biotechnology, Lyell Immunopharma, Allogene Therapeutics, Century Therapeutics, and Arcellx
10-K for FY2025, filed Mar 4, 2026We face competition from segments of the pharmaceutical, biotechnology and other related markets that pursue the development of TCR-based…View ↗
Loading...
